ArticleFrontiers in pharmacology2025
Two natural products from the seeds of
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The seeds of Citrus reticulata Blanco (Rutaceae) (SCR), a traditional Chinese medicine derived from Citrus, is known for its diverse bioactivities, including potential anti-breast cancer effects, but the mechanism of action remains unclear. Methods: This study aims to elucidate the active ingredients of SCR and their mechanisms of action on estrogen biosynthesis. A comprehensive phytochemical analysis, employing various chromatographic techniques, led to the isolation of 26 compounds from SCR. Results: The effects of these compounds on estrogen biosynthesis were evaluated in human ovarian granulosa-like KGN cells, which play a crucial role in the progression of hormone-dependent breast cancers. Network pharmacology analysis revealed that SCR may influence breast cancer development by modulating phosphorylation-related biological processes and the PI3K/AKT pathway. Among the isolated compounds, Callyspongidipeptide A (Calp) and Hesperetin 7-O-β-D-glucopyranoside (Hesp) exhibited significant inhibitory effects on estrogen biosynthesis. Calp and Hesp selectively regulated the expression of aromatase (Aro) PI.3 and P2 promoters via the PI3K/AKT pathway, inhibiting Aro mRNA and protein expression. Discussion: These findings provide novel insights into the chemopreventive potential of SCR and support its role in the development of therapies aimed at reducing the risk of hormone-related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.